Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization due to heart failure, possibly through glucose-independent mechanisms (1)
A phase III, placebo-controlled treatment trial dapagliflozin (at a dose of 10 mg once daily) or placebo in 4744 assigned patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less (1)
A composite of worsening heart failure (hospitalizati…